Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer

NCT07663513 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancers

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection + Bevacizumab + Paclitaxel + Carboplatin

Sponsor

Fudan University